Combined Therapy of Arterial Hypertension With Triple Fixed-Dose Combination of Amlodipine/Indapamide/Perindopril Arginine in Real Clinical Practice: the Organization and the Main Results of the DOKAZATEL’STVO (Proof) Study

Aim: to assess antihypertensive efficacy of the fixed-dose amlodipine/indapamide/perindopril arginine combination in hypertensive patients in real clinical setting. Methods. We included in the 3-month clinical program 1 599 patients with arterial hypertension (AH) (38.8 % men, mean age 61.6±10 years). Primary outcomes were change of office and ambulatory (home blood pressure monitoring) systolic and diastolic blood pressure (SBP and DBP) from baseline to 3 months and rate of achievement of target BP<140 /90 mmHg. Secondary outcomes included response to the therapy, adherence to treatment and safety. Results. By 3 months office BP decreased from 165.5±15.3/96.2±9.7 to 127.6±8.5/78.3±6.4 mmHg (р<0.001); ambulatory BP - from 146.8±13.0/86.4±7.8 to 128.6±9.0/78.2±5.6 mm Hg (р<0.001). Target office BP <140/90 and ambulatory BP<135/85 mmHg was achieved in 87 and 68.1% of patients, respectively. Adherence score increased from 2.9±1.6 до 5.1±1.0 (р<0.001). Conclusion. Administration of a fixed-dose amlodipine/indapamide/perindopril arginine combination resulted in significant BP decrease and rapid achievement of target office BP in most patients. The combination was safe and well tolerated.